Company intelligence / Profile preview

Tricol International

Portland, Oregon, United States

Ownership: Private
Employees: ~1800
Development stage: Other

Overview

Tricol Biomedical has developed chitosan-based hemostatic products with demonstrated rapid bleeding control efficacy. The company holds over 60 patents with technology documented in over 30 clinical publications. Recent development includes a gastrointestinal hemostasis dressing (patent #11,564,673) capable of controlling serious bleeding for up to 96 hours. The company completed its strongest production year in 2022 despite supply chain disruptions.

Therapeutic areas: HematologyDermatologyOtherGastroenterology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Medline (product distribution)Salvin Dental Specialties (exclusive U.S. dental distributor)NorthStar Sales AllianceOHSU (Oregon Health & Science University, NIH-funded collaboration)

Beyond the preview

Go deeper on Tricol International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tricol International.

Explore the full profile